gemcitabine + cisplatin (Seoul National University Hospital)

This refers to a specific adjuvant treatment protocol evaluated in a Phase II clinical trial conducted by Seoul National University Hospital for resected pancreatic adenocarcinoma. The protocol consists of an induction phase of gemcitabine combined with cisplatin, followed by a chemoradiotherapy phase using gemcitabine as a radiosensitizer, and a final maintenance phase of gemcitabine monotherapy. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by targeting ribonucleotide reductase and incorporating into DNA strands, leading to chain termination. Cisplatin is a platinum-based antineoplastic agent that covalently binds to DNA, forming intra- and inter-strand cross-links that interfere with DNA replication and transcription, ultimately triggering apoptosis. The regimen was designed for patients with curatively resected stage IB-IIB pancreatic adenocarcinoma and demonstrated a 1-year disease-free survival rate of 57.9% with a median overall survival of 33.0 months in clinical evaluation.

Brand names

GemzarPlatinol

Other names

Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabineSNUH adjuvant gemcitabine-cisplatin protocol